original ) (raw )Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
Denis Soulières
Journal of Cellular and Molecular Medicine, 2014
View PDFchevron_right
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
Luis Paz-ares
Journal of Cellular and Molecular Medicine, 2010
View PDFchevron_right
Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
Siow-ming Lee
JNCI Journal of the National Cancer Institute, 2013
View PDFchevron_right
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
A. Gelibter
Annals of Oncology, 2011
View PDFchevron_right
Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders
Chi-li Chung
PLoS ONE, 2013
View PDFchevron_right
Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis
Elena Dragioti
DOAJ (DOAJ: Directory of Open Access Journals), 2021
View PDFchevron_right
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations
Katarzyna Reszka
Oncology Letters, 2017
View PDFchevron_right
Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer
S. Rampal
Lung Cancer, 2013
View PDFchevron_right
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population
Aung Naing
Oncotarget, 2013
View PDFchevron_right
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)
Judith Elbaz
Therapeutic Advances in Medical Oncology
View PDFchevron_right
First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
Thomas Lynch
Journal of Clinical Oncology, 2008
View PDFchevron_right
The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer
Luis Corrales
Lung cancer (Amsterdam, Netherlands), 2015
View PDFchevron_right
Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?
Francesco Sollitto
Journal of Thoracic Disease
View PDFchevron_right
The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
Anna Rachiglio
Cancers
View PDFchevron_right
Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population
Venceslau Hespanhol
Archivos de bronconeumologia, 2017
View PDFchevron_right
Epidermal Growth Factor Receptor Inhibition in Mutation-Positive Non-Small-Cell Lung Cancer: Is Afatinib Better or Simply Newer?
Hak Choy , Robert Pirker , Luis Paz-ares
Journal of Clinical Oncology, 2013
View PDFchevron_right
Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
Jin-Hyuk Choi
The Korean journal of internal medicine, 2017
View PDFchevron_right
Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors
Lukas Amler
Cold Spring Harbor Symposia on Quantitative Biology, 2005
View PDFchevron_right
Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
Mirjana Rajer , Izidor Kern
Radiology and Oncology, 2014
View PDFchevron_right
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
Maria Barzelloni
Clinical lung cancer, 2017
View PDFchevron_right
Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
Mirjana Rajer
Cancer Biology & Therapy, 2016
View PDFchevron_right
Canadian consensus: A new systemic treatment algorithm for advanced EGFR-mutated NSCLC
Parneet Cheema
Current Oncology
View PDFchevron_right
{"__content__"=>"Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive mutations.", "i"=>{"__content__"=>"EGFR"}}
Kunihiko Kobayashi
ESMO open, 2018
View PDFchevron_right
EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)
lucia santome
Cancer Management and Research, 2016
View PDFchevron_right
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
Pieter E Postmus
British Journal of Cancer, 2016
View PDFchevron_right
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
Mark Huberman
Lung Cancer, 2007
View PDFchevron_right
CLINICAL CASE STUDY EGFR mutation positive stage IV non-small-cell lung cancer: treatment beyond progression
devi efrina
View PDFchevron_right
Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review
Corey Carter
Neoplasia (New York, N.Y.), 2018
View PDFchevron_right
The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study
Daniel Breadner
Translational Lung Cancer Research
View PDFchevron_right